Skip Navigation


JAC Advance Access originally published online on May 27, 2009
Journal of Antimicrobial Chemotherapy 2009 64(2):434-435; doi:10.1093/jac/dkp192
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
64/2/434    most recent
dkp192v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stebbing, J.
Right arrow Articles by Jones, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stebbing, J.
Right arrow Articles by Jones, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

A multicentre cohort experience with double-boosted protease inhibitors

Justin Stebbing1, Andrew Scourfield2, Gavin Koh3, Clare Taylor4, Stephen Taylor3, Edmund Wilkins4, Brian Gazzard2, Mark Nelson2 and Rachael Jones2,*

1 Imperial College School of Medicine, Chelsea and Westminster Hospital, London, UK 2 Dept HIV/GUM, Chelsea and Westminster Hospital, London, UK 3 Directorate of Sexual Medicine and HIV, Birmingham Heartlands Hospital, Birmingham, UK 4 Monsall Unit, Department of Infectious Diseases, North Manchester General Hospital, Manchester, UK

* Corresponding author. E-mail: rachael.jones@chelwest.nhs.uk

Keywords: PIs , virological outcomes , HIV

The first 10% of the full text of this article appears below.

Sir,

Double-boosted protease inhibitor (DBPI) therapy has been an option in HIV-infected individuals requiring salvage therapy, including those who have exhausted treatment options, harbour complex resistance mutations or have intolerance to nucleoside reverse transcriptase inhibitors (NRTIs). Studies have shown a range of virological responses1–5 and in a retrospective clinical cohort . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?